Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain

Executive Summary

Court says biosimilar sponsors may provide 180-day notice of marketing prior to FDA approval; Federal Circuit to decide if innovators can seek an injunction under state law if sponsors do not provide application and manufacturing information; Justice Breyer offers FDA invitation to weigh in.

You may also be interested in...



CREATES Act Approaches Finish Line But Legislation May Fail To Launch

Broad bipartisan support and billions in projected savings mean that bill may finally pass. But whether it will work as intended to improve generic access to market remains as questionable as ever.

Biosimilar Litigation: Amgen Sues Samsung Bioepis To Enforce 180-Day Notice Requirement

Although Samsung has not provided 180-day advance notice of commercialization for Eticovo, its recently approved biosimilar to Enbrel, Amgen seeks a preliminary injunction because it has reason to believe the company is prepared to launch ‘imminently.’

Judge Kavanaugh May Be Good US Supreme Court Pick For Pharma

Supreme Court nominee may side with biopharma companies in agency disputes, but it's unclear how he will rule on patent and product liability cases scheduled for review next term.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel